Cytheris
Advancing therapies to rejuvenate and strengthen the immune systems of patients facing cancer, chronic infections, and intensive treatments.
Advancing therapies to rejuvenate and strengthen the immune systems of patients facing cancer, chronic infections, and intensive treatments.
Cytheris is a privately held biopharmaceutical company founded in 1999, focusing on advancing therapies to rejuvenate and strengthen the immune systems of patients facing cancer, chronic infections, and intensive treatments. The company is currently at the clinical stage, specializing in the research and development of treatments for immune modulation. Their therapies are tailored to rebuild and augment the immune systems of patients dealing with cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV, or undergoing lympho-depleting treatments including chemotherapy, radiotherapy, bone marrow transplantation (BMT), and hematopoietic cell transplantation (HCT). Cytheris secured a significant $15.00M Series D investment on 07 June 2010, with contributions from Omnes Capital, Forbion, Innovation Capital, Bioam Gestion, and Caisse de Depot et Placement du Quebec. This strategic investment not only bolstered their financial standing but also underscored investor confidence in the company's innovative approach to addressing critical medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $15.00M | 5 |
|
07 Jun 2010 |
| Debt Financing | $2.30M | 1 |
|
15 Jul 2008 |
| Series B | $30.70M | 4 |
|
25 Oct 2006 |
No recent news or press coverage available for Cytheris.
We care about your data, and we'd love to use cookies make your experience better.